Skip to main content

Table 3 Incidence rates for malignancy, infections and autoimmune disease outcomes by treatment

From: Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Outcomes Abatacept Other bDMARDs csDMARDs
No. of events/ no. of patients IR (95% CI)* No. of events/ no. of patients IR (95% CI)* No. of events/ no. of patients IR (95% CI)*
Overall malignancy 22/1099 0.76 (0.47, 1.15) 27/2592 0.50 (0.33, 0.72) 24/1093 0.86 (0.55, 1.27)
 Lung 1/1099 0.012 (0.00, 0.07) 1/2592 0.02 (0.00, 0.10) 0/1093 0.00 (0.00, 0.13)
 NMSC 20/1099 0.55 (0.40, 0.73) 25/2592 0.46 (0.30, 0.68) 20/1093 0.71 (0.43, 1.10)
Hospitalized infections 37/1496 1.63 (1.15, 2.24) 135/3490 1.78 (1.49, 2.11) 77/1520 1.90 (1.50, 2.38)
 Opportunistic 2/1496 0.09 (0.01, 0.31) 6/3490 0.08 (0.03, 0.17) 3/1520 0.07 (0.02, 0.21)
 Pneumonia 13/1496 0.57 (0.30, 0.97) 80/3490 1.04 (0.82, 1.29) 50/1520 1.03 (0.79, 1.33)
Lupus 1/1496 0.04 (0.00, 0.24) 0/3490 0.00 (0.00, 0.05) 3/1520 0.07 (0.02, 0.21)
Psoriasis 15/1496 0.66 (0.37, 1.09) 30/3490 0.39 (0.26, 0.55) 15/1520 0.36 (0.20, 0.59)
Multiple sclerosis 1/1484 0.04 (0.00, 0.24) 0/3471 0.00 (0.00, 0.05) 0/1515 0.00 (0.00, 0.09)
All hospitalizations 637/1496 28.83 (26.64, 31.16) 2001/3490 28.26 (27.03, 29.53) 1292/1520 32.53 (30.78, 34.36)
All deaths 128/1496 2.99 (2.49, 3.55) 162/3490 2.16 (1.84, 2.52) 117/1520 2.78 (2.30, 3.33)
  1. There were no events for breast cancer, lymphoma or tuberculosis in any treatment group
  2. *Per 100 patient-years
  3. Patients with prior history of malignancy or multiple sclerosis were excluded
  4. Deaths from all causes within 1 year of last use of abatacept or of last study observation for control subjects
  5. bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence rate, NMSC non-melanoma skin cancer
\